Y. Samyshkin

发表

Estimating the impact of better management of glycaemic control in adults with Type 1 and Type 2 diabetes on the number of clinical complications and the associated financial benefit

M. Baxter, R. Hudson, J. Mahon, 2016, Diabetic medicine : a journal of the British Diabetic Association.

Patient Heterogeneity in Health Economic Decision Models for Chronic Obstructive Pulmonary Disease: Are Current Models Suitable to Evaluate Personalized Medicine?

A. Briggs, M. Hoogendoorn, R. Hansen, 2016, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

Modeling the lifetime costs of insulin glargine and insulin detemir in type 1 and type 2 diabetes patients in Canada: a meta-analysis and a cost-minimization analysis

D. Wright, Y. Samyshkin, Anne-Laure Guillermin, 2011, Journal of medical economics.

A framework and toolkit for capturing the communicable disease programmes within health systems: tuberculosis control as an illustrative example.

R. Atun, R. Coker, F. Drobniewski, 2004, European journal of public health.

Cost-effectiveness of roflumilast in combination with bronchodilator therapies in patients with severe and very severe COPD in Switzerland

Y. Samyshkin, M. Schlunegger, S. Haefliger, 2013, International journal of chronic obstructive pulmonary disease.

Barriers to sustainable tuberculosis control in the Russian Federation health system.

R. Atun, R. Coker, I. Fedorin, 2005, Bulletin of the World Health Organization.

Feasibility Study of a Network Meta-Analysis and Unanchored Population-Adjusted Indirect Treatment Comparison of Niraparib, Olaparib, and Bevacizumab as Maintenance Therapies in Patients with Newly Diagnosed Advanced Ovarian Cancer

R. Coleman, Y. Samyshkin, D. Lorusso, 2022, Cancers.

Y. Samyshkin, D. Lorusso, H. Guy, 2020, Cancers.

High levels of healthcare utilization prior to diagnosis in idiopathic pulmonary arterial hypertension support the feasibility of an early diagnosis algorithm: the SPHInX project

R. Bergemann, D. Kiely, Y. Samyshkin, 2018, Pulmonary circulation.

Costs and outcomes of tuberculosis control in the Russian Federation: retrospective cohort analysis.

R. Atun, Y. Balabanova, R. Coker, 2006, Health policy and planning.

An Epidemiology Model for Estimating the Numbers of US Patients With Multiple Myeloma by Line of Therapy and Treatment Exposure.

C. Hogea, Y. Samyshkin, L. Sansbury, 2022, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

Health system frailties in tuberculosis service provision in Russia: an analysis through the lens of formal nutritional support.

R. Atun, R. Coker, I. Fedorin, 2005, Public health.

Cost-effectiveness of roflumilast as an add-on treatment to long-acting bronchodilators in the treatment of COPD associated with chronic bronchitis in the United Kingdom

E. Bateman, A. Briggs, Y. Samyshkin, 2013, The European Journal of Health Economics.

Cost-Effectiveness of Stroke Unit Care Followed by Early Supported Discharge

C. Wolfe, A. Mcguire, Y. Samyshkin, 2009, Stroke.

Health-systems efficiency in the Russian Federation: tuberculosis control.

Alexei Korobitsyn, Katherine Floyd, K. Floyd, 2006, Bulletin of the World Health Organization.

Tuberculosis control in Samara Oblast, Russia: institutional and regulatory environment.

R. Atun, Y. Balabanova, R. Coker, 2003, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

Mental health reform in the Russian Federation: an integrated approach to achieve social inclusion and recovery.

Rachel Jenkins, R. Atun, D. Goldberg, 2007, Bulletin of the World Health Organization.

External Validation of Health Economic Decision Models for Chronic Obstructive Pulmonary Disease (COPD): Report of the Third COPD Modeling Meeting.

Reiner Leidl, Andrew H Briggs, Talitha L Feenstra, 2017, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

Cost-effectiveness models for chronic obstructive pulmonary disease: cross-model comparison of hypothetical treatment scenarios.

A. Briggs, S. Sullivan, M. Hoogendoorn, 2014, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

Long-term clinical and economic outcomes associated with liraglutide versus sitagliptin therapy when added to metformin in the treatment of type 2 diabetes: a CORE Diabetes Model analysis

Won Chan Lee, Y. Samyshkin, J. Langer, 2012, Journal of medical economics.

Long-term cost-consequence analysis of exenatide once weekly vs sitagliptin or pioglitazone for the treatment of type 2 diabetes patients in the United States

J. Best, M. Deyoung, J. Gaebler, 2012, Journal of medical economics.

Utilising artificial intelligence to determine patients at risk of a rare disease: idiopathic pulmonary arterial hypertension

R. Bergemann, V. Salvatelli, O. Doyle, 2019, Pulmonary circulation.

Mental health care reforms in Europe: Rehabilitation and social inclusion of people with mental illness in Russia.

Rachel Jenkins, R. Atun, D. McDaid, 2010, Psychiatric Services.

Belantamab mafodotin for the treatment of relapsed/refractory multiple myeloma in heavily pretreated patients: a US cost-effectiveness analysis

C. Hogea, Y. Samyshkin, J. Tosh, 2021, Expert review of hematology.

Long-term cost-utility analysis of exenatide once weekly versus insulin glargine for the treatment of type 2 diabetes patients in the US

J. Best, S. Brunell, Y. Samyshkin, 2012, Journal of medical economics.

Cost-effectiveness of available treatment options for patients suffering from severe COPD in the UK: a fully incremental analysis

Y. Samyshkin, S. Humphreys, N. Hertel, 2012, International journal of chronic obstructive pulmonary disease.

Seasonal variation and hospital utilization for tuberculosis in Russia: hospitals as social care institutions.

R. Atun, R. Coker, I. Fedorin, 2005, European journal of public health.

Budget Impact of Belantamab Mafodotin (Belamaf) Adoption in the Treatment of Patients with Relapsed or Refractory Multiple Myeloma in the United States

C. Hogea, Y. Samyshkin, J. Tosh, 2021, ClinicoEconomics and outcomes research : CEOR.

Cost-effectiveness of cetuximab, bevacizumab, and panitumumab in first-line treatment of metastatic colorectal cancer (mCRC) for patients with KRAS wild-type (wt) tumors in the United Kingdom.

Y. Samyshkin, I. Griebsch, N. Hertel, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Estimating the impact of better management of glycaemic control in adults with Type 1 and Type 2 diabetes on the number of clinical complications and the associated financial benefit

M. Baxter, R. Hudson, J. Mahon, 2016, Diabetic medicine : a journal of the British Diabetic Association.

Mental Health Reform in Russia –an integrated approach to achieve social inclusion and recovery

Rachel Jenkins, D. Goldberg, D. McDaid, 2007 .